VJHemOnc is committed to improving our service to you

IMW 2019 | PROMISE: why early detection of MGUS is vital to reducing MM incidence

VJHemOnc is committed to improving our service to you

Irene Ghobrial, Kenneth Anderson and Robert Kyle

Irene M. Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, and Robert Kyle, MD, Mayo Clinic, Rochester, MN, here discuss the PROMISE study in a roundtable meeting at the International Myeloma Workshop (IMW) 2019, in Boston, MA. They highlight why detecting MGUS is crucial to reducing the instance of progression to MM, and how the PROMISE study will be influential in the future of myeloma-related screening program development.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter